Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-07

AUTHORS

George Dranitsaris, Lesley G Shane, Jean-Philippe Galanaud, Gunar Stemer, Philippe Debourdeau, Seth Woodruff

ABSTRACT

BACKGROUND: International guidelines recommend extended duration secondary prophylaxis in cancer patients who develop primary venous thromboembolism (VTE). Agent selection is guided in part by one large randomized trial (i.e., CLOT; Lee et al., N Engl J Med 349:146-53, 2003) which demonstrated that dalteparin reduced the relative risk of recurrence by 52% compared with oral vitamin K antagonists (VKA; HR = 0.48, 95% CI, 0.30 to 0.77). In a subgroup analysis from that same trial, patients with renal impairment also derived benefit with dalteparin (VTE rates = 3% vs. 17%; p = 0.011). To measure the economic value of secondary VTE prophylaxis with dalteparin, a patient-level pharmacoeconomic analysis was conducted from the Austrian and French healthcare system perspectives. METHODS: Chapter 1 Healthcare resource use collected during the CLOT trial was extracted and converted into direct cost estimates. Incremental cost differences between the dalteparin and VKA groups were then combined with health state utilities to measure the cost per quality-adjusted life year (QALY) gained. RESULTS: The dalteparin group had significantly higher costs than the VKA group in both countries (Austria: dalteparin = €2687 vs. VKA = €2012; France: dalteparin = €2053 vs. VKA = €1352: p < 0.001). However, when the incremental costs were combined with the utility gain, dalteparin had a cost of €6600 and €4900 per QALY gained in Austria and France, respectively. The analyses in patients with renal impairment suggested an even better economic profile, with the cost per QALY gained being less than €4000 in both countries. CONCLUSIONS: Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer. More... »

PAGES

2093-2102

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2

DOI

http://dx.doi.org/10.1007/s00520-017-3610-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1083842709

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28204995


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Austria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dalteparin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Venous Thromboembolism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin K", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Augmentium Pharma Consulting (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.459408.4", 
          "name": [
            "Augmentium Pharma Consulting Inc, 283 Danforth Ave, Suite 448 M4K 1N2, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dranitsaris", 
        "givenName": "George", 
        "id": "sg:person.01036510774.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036510774.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shane", 
        "givenName": "Lesley G", 
        "id": "sg:person.0712705253.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712705253.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital of Montpellier", 
          "id": "https://www.grid.ac/institutes/grid.157868.5", 
          "name": [
            "Montpellier University Hospital, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Galanaud", 
        "givenName": "Jean-Philippe", 
        "id": "sg:person.01232632524.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232632524.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vienna General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411904.9", 
          "name": [
            "Vienna General Hospital, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stemer", 
        "givenName": "Gunar", 
        "id": "sg:person.01075516054.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075516054.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Sainte Catherine", 
          "id": "https://www.grid.ac/institutes/grid.482015.a", 
          "name": [
            "Institut Sainte Catherine, Avignon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Debourdeau", 
        "givenName": "Philippe", 
        "id": "sg:person.01224577007.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224577007.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Woodruff", 
        "givenName": "Seth", 
        "id": "sg:person.015700301775.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015700301775.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40258-014-0130-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000246041", 
          "https://doi.org/10.1007/s40258-014-0130-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1538-7836.2006.01804.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004624260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1538-7836.2006.01804.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004624260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.thromres.2014.11.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012980372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-016-1386-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014677169", 
          "https://doi.org/10.1007/s11239-016-1386-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-016-1386-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014677169", 
          "https://doi.org/10.1007/s11239-016-1386-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s39964", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015048941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015902157", 
          "https://doi.org/10.1038/sj.bjc.6605417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015902157", 
          "https://doi.org/10.1038/sj.bjc.6605417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03256152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016443579", 
          "https://doi.org/10.1007/bf03256152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020566522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70232-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020618217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.49.1118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022692210"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa025313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024707641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-006-0062-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024921848", 
          "https://doi.org/10.1007/s00520-006-0062-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-006-0062-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024921848", 
          "https://doi.org/10.1007/s00520-006-0062-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01262566", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025411356", 
          "https://doi.org/10.1007/bf01262566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01262566", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025411356", 
          "https://doi.org/10.1007/bf01262566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0021-9681(87)90019-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029030291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2015.9243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032108796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/0973-1482.39685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032170623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000022400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034488207"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1538-7836.2003.00396.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038182500"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00129784-200404050-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038658520", 
          "https://doi.org/10.2165/00129784-200404050-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00129784-200404050-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038658520", 
          "https://doi.org/10.2165/00129784-200404050-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.11-2296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039499818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s85635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041106407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr392", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048198947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-015-0187-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049493237", 
          "https://doi.org/10.1007/s12325-015-0187-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.3271", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050418707"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s126379", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052050478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.27772", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053084726"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.suponc.2010.09.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054750578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2165/11314740-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077966207"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07", 
    "datePublishedReg": "2017-07-01", 
    "description": "BACKGROUND: International guidelines recommend extended duration secondary prophylaxis in cancer patients who develop primary venous thromboembolism (VTE). Agent selection is guided in part by one large randomized trial (i.e., CLOT; Lee et al., N Engl J Med 349:146-53, 2003) which demonstrated that dalteparin reduced the relative risk of recurrence by 52% compared with oral vitamin K antagonists (VKA; HR\u00a0=\u00a00.48, 95% CI, 0.30 to 0.77). In a subgroup analysis from that same trial, patients with renal impairment also derived benefit with dalteparin (VTE rates\u00a0=\u00a03% vs. 17%; p\u00a0=\u00a00.011). To measure the economic value of secondary VTE prophylaxis with dalteparin, a patient-level pharmacoeconomic analysis was conducted from the Austrian and French healthcare system perspectives.\nMETHODS: Chapter 1 Healthcare resource use collected during the CLOT trial was extracted and converted into direct cost estimates. Incremental cost differences between the dalteparin and VKA groups were then combined with health state utilities to measure the cost per quality-adjusted life year (QALY) gained.\nRESULTS: The dalteparin group had significantly higher costs than the VKA group in both countries (Austria: dalteparin\u00a0=\u00a0\u20ac2687 vs. VKA\u00a0=\u00a0\u20ac2012; France: dalteparin\u00a0=\u00a0\u20ac2053 vs. VKA\u00a0=\u00a0\u20ac1352: p\u00a0<\u00a00.001). However, when the incremental costs were combined with the utility gain, dalteparin had a cost of \u20ac6600 and \u20ac4900 per QALY gained in Austria and France, respectively. The analyses in patients with renal impairment suggested an even better economic profile, with the cost per QALY gained being less than \u20ac4000 in both countries.\nCONCLUSIONS: Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00520-017-3610-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1103473", 
        "issn": [
          "0941-4355", 
          "1433-7339"
        ], 
        "name": "Supportive Care in Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "name": "Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria", 
    "pagination": "2093-2102", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "13f1a0cf82b5631a4296b157428aa018d512317fe95cf14003b8d7df2a3d685f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28204995"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9302957"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00520-017-3610-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1083842709"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00520-017-3610-2", 
      "https://app.dimensions.ai/details/publication/pub.1083842709"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99824_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00520-017-3610-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      71 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00520-017-3610-2 schema:about N046cec4041584fc19998b711ac2550f9
2 N048b82828ddf48318473a529e8522392
3 N0b923a12a11a4cfda91d80cfb2220d32
4 N0b97fe1d59554ff78089d17a748094eb
5 N0dcfa00788904d30b4882f8d5e4064a9
6 N17033314db7d492b971f27061485b764
7 N22e2d0fc373d4207803a2a6c81eac2ed
8 N3751f599230a4bc1a71a0ec2979a729f
9 N5d0c083dacdd4954bddb1d1ff24b522b
10 N64654e2058964610b5aef14ec0b4caf8
11 N6c401589dc344470a453112849e51a75
12 N6ef69711727146b393fbb322f2f23117
13 Na6ee2901db594da08d43d69a6c407996
14 Nb64c65bd37be43c08e436778d1d08447
15 anzsrc-for:11
16 anzsrc-for:1117
17 schema:author N31783a2c824d44ee9e7a7a95931e7f5b
18 schema:citation sg:pub.10.1007/bf01262566
19 sg:pub.10.1007/bf03256152
20 sg:pub.10.1007/s00520-006-0062-5
21 sg:pub.10.1007/s11239-016-1386-8
22 sg:pub.10.1007/s12325-015-0187-3
23 sg:pub.10.1007/s40258-014-0130-9
24 sg:pub.10.1038/sj.bjc.6605417
25 sg:pub.10.2165/00129784-200404050-00005
26 https://doi.org/10.1001/jama.2015.9243
27 https://doi.org/10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o
28 https://doi.org/10.1002/cncr.27772
29 https://doi.org/10.1016/0021-9681(87)90019-1
30 https://doi.org/10.1016/j.suponc.2010.09.027
31 https://doi.org/10.1016/j.thromres.2014.11.024
32 https://doi.org/10.1016/s1470-2045(09)70232-3
33 https://doi.org/10.1046/j.1538-7836.2003.00396.x
34 https://doi.org/10.1056/nejmoa025313
35 https://doi.org/10.1093/annonc/mdr392
36 https://doi.org/10.1111/j.1538-7836.2006.01804.x
37 https://doi.org/10.1159/000022400
38 https://doi.org/10.1200/jco.2009.22.3271
39 https://doi.org/10.1200/jco.2013.49.1118
40 https://doi.org/10.1378/chest.11-2296
41 https://doi.org/10.2147/ceor.s126379
42 https://doi.org/10.2147/ceor.s39964
43 https://doi.org/10.2147/ceor.s85635
44 https://doi.org/10.2165/11314740-000000000-00000
45 https://doi.org/10.4103/0973-1482.39685
46 schema:datePublished 2017-07
47 schema:datePublishedReg 2017-07-01
48 schema:description BACKGROUND: International guidelines recommend extended duration secondary prophylaxis in cancer patients who develop primary venous thromboembolism (VTE). Agent selection is guided in part by one large randomized trial (i.e., CLOT; Lee et al., N Engl J Med 349:146-53, 2003) which demonstrated that dalteparin reduced the relative risk of recurrence by 52% compared with oral vitamin K antagonists (VKA; HR = 0.48, 95% CI, 0.30 to 0.77). In a subgroup analysis from that same trial, patients with renal impairment also derived benefit with dalteparin (VTE rates = 3% vs. 17%; p = 0.011). To measure the economic value of secondary VTE prophylaxis with dalteparin, a patient-level pharmacoeconomic analysis was conducted from the Austrian and French healthcare system perspectives. METHODS: Chapter 1 Healthcare resource use collected during the CLOT trial was extracted and converted into direct cost estimates. Incremental cost differences between the dalteparin and VKA groups were then combined with health state utilities to measure the cost per quality-adjusted life year (QALY) gained. RESULTS: The dalteparin group had significantly higher costs than the VKA group in both countries (Austria: dalteparin = €2687 vs. VKA = €2012; France: dalteparin = €2053 vs. VKA = €1352: p < 0.001). However, when the incremental costs were combined with the utility gain, dalteparin had a cost of €6600 and €4900 per QALY gained in Austria and France, respectively. The analyses in patients with renal impairment suggested an even better economic profile, with the cost per QALY gained being less than €4000 in both countries. CONCLUSIONS: Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree false
52 schema:isPartOf N0caf9ed3005946b4a44b11e83d7cff32
53 Nc85aba322fa441bf8898ea6546ad7815
54 sg:journal.1103473
55 schema:name Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria
56 schema:pagination 2093-2102
57 schema:productId N40753841e0c24e09b1af4901de1e7117
58 N6e984015c6de41bf9a387637ebb99c4e
59 N8f4b3cbfd012456f8dd45110da864b2b
60 Nc0c22db4494f415a9cf7956c30f0d1ed
61 Nc8e8d4b299064d07bdacdd92344d4a10
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083842709
63 https://doi.org/10.1007/s00520-017-3610-2
64 schema:sdDatePublished 2019-04-11T09:36
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher Ne9d1b77ecd014f9ebaddd6c45e171bd2
67 schema:url https://link.springer.com/10.1007%2Fs00520-017-3610-2
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N046cec4041584fc19998b711ac2550f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Female
73 rdf:type schema:DefinedTerm
74 N048b82828ddf48318473a529e8522392 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Neoplasms
76 rdf:type schema:DefinedTerm
77 N0b923a12a11a4cfda91d80cfb2220d32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Vitamin K
79 rdf:type schema:DefinedTerm
80 N0b97fe1d59554ff78089d17a748094eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Austria
82 rdf:type schema:DefinedTerm
83 N0caf9ed3005946b4a44b11e83d7cff32 schema:issueNumber 7
84 rdf:type schema:PublicationIssue
85 N0dcfa00788904d30b4882f8d5e4064a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Middle Aged
87 rdf:type schema:DefinedTerm
88 N17033314db7d492b971f27061485b764 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Humans
90 rdf:type schema:DefinedTerm
91 N1c044da681b2482ca2e90a39bad273fa rdf:first sg:person.01224577007.14
92 rdf:rest N7fac64c49f2f40418230b87732826fce
93 N22e2d0fc373d4207803a2a6c81eac2ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Anticoagulants
95 rdf:type schema:DefinedTerm
96 N31783a2c824d44ee9e7a7a95931e7f5b rdf:first sg:person.01036510774.09
97 rdf:rest N967de440d2724ae189b5b262999d9def
98 N3751f599230a4bc1a71a0ec2979a729f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Recurrence
100 rdf:type schema:DefinedTerm
101 N40753841e0c24e09b1af4901de1e7117 schema:name nlm_unique_id
102 schema:value 9302957
103 rdf:type schema:PropertyValue
104 N4b9e745903b34a7f9c8f2270bce77e5c rdf:first sg:person.01075516054.30
105 rdf:rest N1c044da681b2482ca2e90a39bad273fa
106 N5d0c083dacdd4954bddb1d1ff24b522b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Dalteparin
108 rdf:type schema:DefinedTerm
109 N64654e2058964610b5aef14ec0b4caf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Cost-Benefit Analysis
111 rdf:type schema:DefinedTerm
112 N6c401589dc344470a453112849e51a75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Venous Thromboembolism
114 rdf:type schema:DefinedTerm
115 N6e984015c6de41bf9a387637ebb99c4e schema:name readcube_id
116 schema:value 13f1a0cf82b5631a4296b157428aa018d512317fe95cf14003b8d7df2a3d685f
117 rdf:type schema:PropertyValue
118 N6ef69711727146b393fbb322f2f23117 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Male
120 rdf:type schema:DefinedTerm
121 N7fac64c49f2f40418230b87732826fce rdf:first sg:person.015700301775.03
122 rdf:rest rdf:nil
123 N8f4b3cbfd012456f8dd45110da864b2b schema:name pubmed_id
124 schema:value 28204995
125 rdf:type schema:PropertyValue
126 N967de440d2724ae189b5b262999d9def rdf:first sg:person.0712705253.03
127 rdf:rest Nd5f0e815cccd47c494d613d8b59e0963
128 Na6ee2901db594da08d43d69a6c407996 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name France
130 rdf:type schema:DefinedTerm
131 Nb64c65bd37be43c08e436778d1d08447 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Quality of Life
133 rdf:type schema:DefinedTerm
134 Nc0c22db4494f415a9cf7956c30f0d1ed schema:name doi
135 schema:value 10.1007/s00520-017-3610-2
136 rdf:type schema:PropertyValue
137 Nc85aba322fa441bf8898ea6546ad7815 schema:volumeNumber 25
138 rdf:type schema:PublicationVolume
139 Nc8e8d4b299064d07bdacdd92344d4a10 schema:name dimensions_id
140 schema:value pub.1083842709
141 rdf:type schema:PropertyValue
142 Nd5f0e815cccd47c494d613d8b59e0963 rdf:first sg:person.01232632524.54
143 rdf:rest N4b9e745903b34a7f9c8f2270bce77e5c
144 Ne9d1b77ecd014f9ebaddd6c45e171bd2 schema:name Springer Nature - SN SciGraph project
145 rdf:type schema:Organization
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
150 schema:name Public Health and Health Services
151 rdf:type schema:DefinedTerm
152 sg:journal.1103473 schema:issn 0941-4355
153 1433-7339
154 schema:name Supportive Care in Cancer
155 rdf:type schema:Periodical
156 sg:person.01036510774.09 schema:affiliation https://www.grid.ac/institutes/grid.459408.4
157 schema:familyName Dranitsaris
158 schema:givenName George
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036510774.09
160 rdf:type schema:Person
161 sg:person.01075516054.30 schema:affiliation https://www.grid.ac/institutes/grid.411904.9
162 schema:familyName Stemer
163 schema:givenName Gunar
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075516054.30
165 rdf:type schema:Person
166 sg:person.01224577007.14 schema:affiliation https://www.grid.ac/institutes/grid.482015.a
167 schema:familyName Debourdeau
168 schema:givenName Philippe
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224577007.14
170 rdf:type schema:Person
171 sg:person.01232632524.54 schema:affiliation https://www.grid.ac/institutes/grid.157868.5
172 schema:familyName Galanaud
173 schema:givenName Jean-Philippe
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232632524.54
175 rdf:type schema:Person
176 sg:person.015700301775.03 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
177 schema:familyName Woodruff
178 schema:givenName Seth
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015700301775.03
180 rdf:type schema:Person
181 sg:person.0712705253.03 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
182 schema:familyName Shane
183 schema:givenName Lesley G
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712705253.03
185 rdf:type schema:Person
186 sg:pub.10.1007/bf01262566 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025411356
187 https://doi.org/10.1007/bf01262566
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/bf03256152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016443579
190 https://doi.org/10.1007/bf03256152
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/s00520-006-0062-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024921848
193 https://doi.org/10.1007/s00520-006-0062-5
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/s11239-016-1386-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014677169
196 https://doi.org/10.1007/s11239-016-1386-8
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/s12325-015-0187-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049493237
199 https://doi.org/10.1007/s12325-015-0187-3
200 rdf:type schema:CreativeWork
201 sg:pub.10.1007/s40258-014-0130-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000246041
202 https://doi.org/10.1007/s40258-014-0130-9
203 rdf:type schema:CreativeWork
204 sg:pub.10.1038/sj.bjc.6605417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015902157
205 https://doi.org/10.1038/sj.bjc.6605417
206 rdf:type schema:CreativeWork
207 sg:pub.10.2165/00129784-200404050-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038658520
208 https://doi.org/10.2165/00129784-200404050-00005
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1001/jama.2015.9243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032108796
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1020566522
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1002/cncr.27772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053084726
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/0021-9681(87)90019-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029030291
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/j.suponc.2010.09.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054750578
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/j.thromres.2014.11.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012980372
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s1470-2045(09)70232-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020618217
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1046/j.1538-7836.2003.00396.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038182500
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1056/nejmoa025313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024707641
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1093/annonc/mdr392 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048198947
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1111/j.1538-7836.2006.01804.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004624260
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1159/000022400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034488207
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1200/jco.2009.22.3271 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050418707
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.2013.49.1118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022692210
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1378/chest.11-2296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039499818
239 rdf:type schema:CreativeWork
240 https://doi.org/10.2147/ceor.s126379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052050478
241 rdf:type schema:CreativeWork
242 https://doi.org/10.2147/ceor.s39964 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015048941
243 rdf:type schema:CreativeWork
244 https://doi.org/10.2147/ceor.s85635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041106407
245 rdf:type schema:CreativeWork
246 https://doi.org/10.2165/11314740-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077966207
247 rdf:type schema:CreativeWork
248 https://doi.org/10.4103/0973-1482.39685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032170623
249 rdf:type schema:CreativeWork
250 https://www.grid.ac/institutes/grid.157868.5 schema:alternateName University Hospital of Montpellier
251 schema:name Montpellier University Hospital, Montpellier, France
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
254 schema:name Pfizer Inc, New York, NY, USA
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.411904.9 schema:alternateName Vienna General Hospital
257 schema:name Vienna General Hospital, Vienna, Austria
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.459408.4 schema:alternateName Augmentium Pharma Consulting (Canada)
260 schema:name Augmentium Pharma Consulting Inc, 283 Danforth Ave, Suite 448 M4K 1N2, Toronto, Canada
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.482015.a schema:alternateName Institut Sainte Catherine
263 schema:name Institut Sainte Catherine, Avignon, France
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...